Skip to main content
. Author manuscript; available in PMC: 2015 Sep 23.
Published in final edited form as: Integr Cancer Sci Ther. 2015 Aug 4;2(4):192–200. doi: 10.15761/icst.1000139

Figure 6.

Figure 6

P2Y1 Receptor blockade or NM23 antagonist significantly suppresses tumor formation in vivo. In separate experiments conducted as described for the images seen in figure 5, with 6 animals/group, the effect of endostatin, EA, MRS2179 or the combination on tumor volume over time was determined. Inset: comparison of control data versus endostatin treatment.